ENTITY

Evaxion Biotech A/S (EVAX US)

18
Analysis
Health Care • Denmark
Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.
more
bullish•Evaxion Biotech A/S
•16 Jan 2025 00:00•Issuer-paid

EVAX: Share Ratio Adjustment

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Share
bullish•Evaxion Biotech A/S
•13 Nov 2024 04:03•Issuer-paid

EVAX: More Exciting Test Results

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Share
bullish•Evaxion Biotech A/S
•31 Oct 2024 23:00•Issuer-paid

EVAX: Beats Estimates and Highlights Trials

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Share
bullish•Evaxion Biotech A/S
•04 Oct 2024 01:00•Issuer-paid

EVAX: Trial Suggests AI Improves Performance

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Share
bullish•Evaxion Biotech A/S
•27 Sep 2024 00:00•Issuer-paid

EVAX: Expanded Deal with MSD Boosts Prospects

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Share
x